

# Patrick A Baeuerle

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11190302/patrick-a-baeuerle-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158  
papers

27,112  
citations

83  
h-index

160  
g-index

160  
ext. papers

28,658  
ext. citations

10.1  
avg, IF

6.87  
L-index

#	Paper	IF	Citations
158	A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. <b>2022</b> , 10,		2
157	TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 109-120	6.1	7
156	Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1452-1462	12.9	6
155	Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?. <i>Cancer and Metastasis Reviews</i> , <b>2020</b> , 39, 969-987	9.6	51
154	Implications of T cell receptor biology on the development of new T cell therapies for cancer. <i>Immunotherapy</i> , <b>2020</b> , 12, 89-103	3.8	5
153	Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. <i>Nature Communications</i> , <b>2019</b> , 10, 2087	17.4	56
152	Development of T-Cell-Engaging Bispecific Antibody Blinatumomab (Blinicyto <sup>®</sup> ) for Treatment of B-Cell Malignancies <b>2018</b> , 111-130		2
151	Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	19
150	Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. <i>Current Clinical Pharmacology</i> , <b>2018</b> , 13, 55-64	2.5	12
149	Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection. <i>Antiviral Research</i> , <b>2017</b> , 141, 155-164	10.8	11
148	Bispecific T cell engager (BiTE <sup>®</sup> ) antibody constructs can mediate bystander tumor cell killing. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183390	3.7	43
147	Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. <i>Experimental Hematology and Oncology</i> , <b>2017</b> , 6, 14	7.8	43
146	Bispecific T-Cell Engager (BiTE <sup>®</sup> ) Antibody Construct Blinatumomab BiTE for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1104-11	2.2	273
145	Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141669	3.7	16
144	CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. <i>Blood</i> , <b>2014</b> , 123, 356-65	2.2	132
143	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1549-57	6.1	94
142	CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. <i>MAbs</i> , <b>2014</b> , 6, 1571-84	6.6	63

141	Resurgence of Bispecific Antibodies <b>2013</b> , 529-543		1
140	The activity of T cells against paediatric liver tumour cells and spheroids in cell culture. <i>Liver International</i> , <b>2013</b> , 33, 127-36	7.9	33
139	Targeting T cells to tumor cells using bispecific antibodies. <i>Current Opinion in Chemical Biology</i> , <b>2013</b> , 17, 385-92	9.7	134
138	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. <i>Blood</i> , <b>2012</b> , 119, 6226-33	2.2	328
137	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i> , <b>2012</b> , 120, 5185-7	2.2	389
136	Blinatumomab: a historical perspective. <i>Pharmacology &amp; Therapeutics</i> , <b>2012</b> , 136, 334-42	13.9	221
135	The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. <i>PLoS ONE</i> , <b>2012</b> , 7, e36412	3.7	20
134	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 465-74	12.9	96
133	Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2664-73	6.1	95
132	Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. <i>Current Pharmaceutical Biotechnology</i> , <b>2012</b> , 13, 1399-408	2.6	9
131	The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. <i>Transplant Immunology</i> , <b>2011</b> , 25, 133-40	1.7	2
130	Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. <i>Journal of Immunotherapy</i> , <b>2011</b> , 34, 597-605	5	33
129	Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. <i>Experimental Cell Research</i> , <b>2011</b> , 317, 1255-60	4.2	140
128	Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2493-8	2.2	714
127	Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. <i>MAbs</i> , <b>2011</b> , 3, 31-7	6.6	22
126	Bispecific T Cell Engager for Cancer Therapy <b>2011</b> , 273-287		1
125	Passive immunotherapy by T cell-engaging bispecific antibodies <b>2011</b> , 250-262		
124	Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. <i>PLoS ONE</i> , <b>2010</b> , 5, e13474	3.7	58

123	Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. <i>Urologia Internationalis</i> , <b>2010</b> , 85, 386-95	1.9	26
122	T cell-engaging BiTE antibodies specific for EGFR potentially eliminate KRAS- and BRAF-mutated colorectal cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 12605-10	11.5	113
121	Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 1197-209	7.4	125
120	Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. <i>Cancer Cell International</i> , <b>2010</b> , 10, 44	6.4	83
119	Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 95-109	7.4	29
118	Nuclear signalling by tumour-associated antigen EpCAM. <i>Nature Cell Biology</i> , <b>2009</b> , 11, 162-71	23.4	522
117	On the abundance of EpCAM on cancer stem cells. <i>Nature Reviews Cancer</i> , <b>2009</b> , 9, 143; author reply 143	31.3	105
116	Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. <i>Leukemia Research</i> , <b>2009</b> , 33, 465-73	2.7	61
115	The emerging role of EpCAM in cancer and stem cell signaling. <i>Cancer Research</i> , <b>2009</b> , 69, 5627-9	10.1	405
114	Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 886-91	1.9	92
113	Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. <i>Immunobiology</i> , <b>2009</b> , 214, 441-53	3.4	140
112	Bispecific T-cell engaging antibodies for cancer therapy. <i>Cancer Research</i> , <b>2009</b> , 69, 4941-4	10.1	424
111	Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 452-64	5.4	52
110	Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 341-52	5	63
109	Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE □ Antibody Blinatumomab.. <i>Blood</i> , <b>2009</b> , 114, 4793-4793	2.2	2
108	Report of a Phase II Trial of Single-Agent BiTE □ Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , <b>2009</b> , 114, 840-840	2.2	4
107	BiTE: Teaching antibodies to engage T-cells for cancer therapy. <i>Current Opinion in Molecular Therapeutics</i> , <b>2009</b> , 11, 22-30		85
106	Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. <i>Science</i> , <b>2008</b> , 321, 974-7	33.3	802

105	Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. <i>Cancer Research</i> , <b>2008</b> , 68, 143-51	10.1	63
104	Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction. <i>Heart and Vessels</i> , <b>2008</b> , 23, 230-42	2.1	4
103	Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.. <i>Blood</i> , <b>2008</b> , 112, 1926-1926	2.2	15
102	Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL. <i>Blood</i> , <b>2008</b> , 112, 267-267	2.2	8
101	Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. <i>Cancer Research</i> , <b>2007</b> , 67, 3927-35	10.1	77
100	Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 459-68	7.4	11
99	The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1551-63	7.4	104
98	Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 798-807	5	139
97	A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. <i>Molecular Immunology</i> , <b>2007</b> , 44, 916-25	4.3	28
96	A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. <i>Molecular Immunology</i> , <b>2007</b> , 44, 1743-53	4.3	3
95	CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. <i>Molecular Immunology</i> , <b>2007</b> , 44, 1935-43	4.3	83
94	T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 503-14	7.4	84
93	Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 785-96	7.4	44
92	Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 483-8	4.9	164
91	A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 2530-8	7.5	40
90	Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. <i>Molecular Immunology</i> , <b>2006</b> , 43, 763-71	4.3	232
89	High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. <i>Molecular Immunology</i> , <b>2006</b> , 43, 1183-93	4.3	109
88	MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. <i>Molecular Immunology</i> , <b>2006</b> , 43, 1129-43	4.3	198

87	Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. <i>Journal of Immunotherapy</i> , <b>2006</b> , 29, 477-88	5	14
86	BiTEs: bispecific antibody constructs with unique anti-tumor activity. <i>Drug Discovery Today</i> , <b>2005</b> , 10, 1237-44	8.8	192
85	Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. <i>International Journal of Cancer</i> , <b>2005</b> , 115, 98-104	7.5	247
84	Epithelial tight junction proteins as potential antibody targets for pancreatic carcinoma therapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 431-45	7.4	47
83	Highly efficient antigen targeting to M-DC8+ dendritic cells via Fcγ3R/CD16-specific antibody conjugates. <i>International Immunology</i> , <b>2005</b> , 17, 539-47	4.9	17
82	Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. <i>Cancer Research</i> , <b>2005</b> , 65, 2882-9	10.1	116
81	Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. <i>FASEB Journal</i> , <b>2005</b> , 19, 246-8	0.9	43
80	Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. <i>Molecular Pharmacology</i> , <b>2004</b> , 65, 880-9	4.3	46
79	A revival of bispecific antibodies. <i>Trends in Biotechnology</i> , <b>2004</b> , 22, 238-44	15.1	129
78	A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. <i>Molecular Immunology</i> , <b>2004</b> , 41, 511-511	4.3	
77	A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. <i>Molecular Immunology</i> , <b>2004</b> , 41, 511-8	4.3	2
76	T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. <i>Journal of Immunology</i> , <b>2003</b> , 170, 4397-402	5.3	160
75	Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2003</b> , 129, 341-8	4.9	21
74	Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. <i>International Journal of Cancer</i> , <b>2003</b> , 105, 241-8	7.5	25
73	Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. <i>International Immunology</i> , <b>2003</b> , 15, 789-96	4.9	22
72	A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-α. <i>Journal of Immunology</i> , <b>2003</b> , 170, 5089-94	5.3	78
71	Bispecific antibodies for polyclonal T-cell engagement. <i>Current Opinion in Molecular Therapeutics</i> , <b>2003</b> , 5, 413-9		19
70	In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancreatic carcinoma treatment. <i>International Journal of Cancer</i> , <b>2002</b> , 100, 101-10	7.5	75

69	Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. <i>International Journal of Cancer</i> , <b>2002</b> , 100, 690-7	7.5	240
68	Combined transcriptome and genome analysis of single micrometastatic cells. <i>Nature Biotechnology</i> , <b>2002</b> , 20, 387-92	44.5	245
67	Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 1646-55	6.1	55
66	Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. <i>Circulation</i> , <b>2001</b> , 103, 1396-402	16.7	103
65	Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. <i>Molecular Cell</i> , <b>2001</b> , 7, 1059-69	17.6	85
64	Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. <i>Free Radical Biology and Medicine</i> , <b>2000</b> , 28, 1317-27	7.8	566
63	The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 29779-87	5.4	99
62	Reactive Oxygen Species as Costimulatory Signals of Cytokine-Induced NF- $\kappa$ B Activation Pathways <b>2000</b> , 181-201		3
61	Structural analysis, expression, and chromosomal localization of the mouse ikba gene. <i>Immunogenetics</i> , <b>1999</b> , 49, 395-403	3.2	18
60	IKAP is a scaffold protein of the IkappaB kinase complex. <i>Nature</i> , <b>1998</b> , 395, 292-6	50.4	275
59	Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle?. <i>Current Biology</i> , <b>1998</b> , 8, R19-22	6.3	256
58	IkappaB-NF-kappaB structures: at the interface of inflammation control. <i>Cell</i> , <b>1998</b> , 95, 729-31	56.2	409
57	Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. <i>Gastroenterology</i> , <b>1998</b> , 115, 357-69	13.3	592
56	Regulation of Gene Expression by Oxidative Stress. <i>Advances in Molecular and Cell Biology</i> , <b>1998</b> , 25, 15-44		2
55	Kinases in Pro-Inflammatory Signal Transduction Pathways: New Opportunities for Drug Discovery. <i>Annual Reports in Medicinal Chemistry</i> , <b>1998</b> , 233-242	1.6	3
54	Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 23435-9	5.4	116
53	Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 22278-84	5.4	88
52	trans-Activation of the HIV type 1 promoter by 7,8-dihydroneopterin in vitro. <i>AIDS Research and Human Retroviruses</i> , <b>1997</b> , 13, 173-8	1.6	17

51	NF- $\kappa$ B as a Frequent Target for Immunosuppressive and Anti-Inflammatory Molecules**This article was accepted for publication on 27 September 1996.. <i>Advances in Immunology</i> , <b>1997</b> , 111-137	5.6	457
50	Reactive Oxygen Intermediates as Primary Signals and Second Messengers in the Activation of Transcription Factors <b>1997</b> , 239-259		12
49	Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. <i>Methods</i> , <b>1997</b> , 11, 301-12	4.6	231
48	Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 1901-9	9.4	117
47	Activate NF-kappa B or die?. <i>Current Biology</i> , <b>1997</b> , 7, R94-6	6.3	450
46	Endoplasmicreticulum-induced signal transduction and gene expression. <i>Trends in Cell Biology</i> , <b>1997</b> , 7, 50-5	18.3	62
45	The ER-overload response: activation of NF-kappa B. <i>Trends in Biochemical Sciences</i> , <b>1997</b> , 22, 63-7	10.3	297
44	Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. <i>FEBS Journal</i> , <b>1997</b> , 244, 45-52		92
43	Cloning of the murine relA (p65 NF-kappa B) gene and comparison to the human gene reveals a distinct first intron. <i>Gene</i> , <b>1996</b> , 176, 119-24	3.8	5
42	Activation of NF-kappa B by ER stress requires both Ca <sup>2+</sup> and reactive oxygen intermediates as messengers. <i>FEBS Letters</i> , <b>1996</b> , 392, 129-36	3.8	174
41	Sex reversal by loss of the C-terminal transactivation domain of human SOX9. <i>Nature Genetics</i> , <b>1996</b> , 13, 230-2	36.3	182
40	Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. <i>Cell</i> , <b>1996</b> , 86, 787-98	56.2	643
39	[15]Identification of transcription factors and their target genes. <i>Methods in Molecular Genetics</i> , <b>1996</b> , 8, 278-297		
38	Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 2119-26	6.1	103
37	The histidine tail of recombinant DNA binding proteins may influence the quality of interaction with DNA. <i>Analytical Biochemistry</i> , <b>1996</b> , 234, 227-30	3.1	11
36	A hydrophobic region within the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF-kappaB activated by different stimuli. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 20392-8	5.4	10
35	Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaB. <i>Advances in Experimental Medicine and Biology</i> , <b>1996</b> , 387, 63-8	3.6	59
34	The Transcription Factor TCF/Elk-1. <i>Advances in Experimental Medicine and Biology</i> , <b>1996</b> , 77-84	3.6	3



33	The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. <i>Chemistry and Biology</i> , <b>1995</b> , 2, 13-22		399
32	Appearance of apparently ubiquitin-conjugated I kappa B-alpha during its phosphorylation-induced degradation in intact cells. <i>Journal of Cell Science</i> , <b>1995</b> , 19, 79-84	5-3	42
31	Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-kappa B. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 27136-42	5-4	147
30	Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 15576-84	5-4	141
29	Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 26419-32	5-4	95
28	Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 7219-26	5-4	135
27	Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. <i>Biochemical Pharmacology</i> , <b>1995</b> , 50, 735-41	6	253
26	Multi-step activation of NF-kappa B/Rel transcription factors. <i>Immunobiology</i> , <b>1995</b> , 193, 116-27	3-4	69
25	A new interference footprinting method for analysing simultaneously protein contacts to phosphate and guanine residues on DNA. <i>Nucleic Acids Research</i> , <b>1995</b> , 23, 1443-4	20.1	7
24	The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. <i>FEBS Journal</i> , <b>1995</b> , 234, 632-40		143
23	Hydrogen peroxide as a potent activator of T lymphocyte functions. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 159-65	6.1	178
22	Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. <i>Hepatology</i> , <b>1995</b> , 22, 613-9	11.2	83
21	Signal Transduction from the Cytoplasm to the Cell Nucleus by NF-B/Rel Transcription Factors <b>1995</b> , 279-303		1
20	Oxygen and the control of gene expression. <i>BioEssays</i> , <b>1994</b> , 16, 497-502	4.1	234
19	Regulation of the transcription factors NF-kappa B and AP-1 by redox changes. <i>Chemico-Biological Interactions</i> , <b>1994</b> , 91, 91-100	5	259
18	Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-kappa B. <i>Methods in Enzymology</i> , <b>1994</b> , 234, 151-63	1.7	134
17	Nuclear factor kappa B, a mediator of lipopolysaccharide effects. <i>Immunobiology</i> , <b>1993</b> , 187, 233-56	3-4	431
16	Brain synapses contain inducible forms of the transcription factor NF-kappa B. <i>Mechanisms of Development</i> , <b>1993</b> , 43, 135-47	1.7	189

15	Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. <i>Nature</i> , <b>1993</b> , 365, 182-5	50.4	1061
14	Potential involvement of the transcription factor NF-kappa B in neurological disorders. <i>Molecular Aspects of Medicine</i> , <b>1993</b> , 14, 171-90	16.7	116
13	Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit. <i>Cell</i> , <b>1992</b> , 68, 1121-33	56.2	370
12	Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). <i>Free Radical Research Communications</i> , <b>1992</b> , 17, 221-37		1141
11	A role for oxygen radicals as second messengers. <i>Trends in Cell Biology</i> , <b>1991</b> , 1, 39-42	18.3	435
10	Proteins controlling the nuclear uptake of NF-kappa B, Rel and dorsal. <i>Trends in Cell Biology</i> , <b>1991</b> , 1, 130-7	18.3	107
9	The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>1991</b> , 1072, 63-80	11.2	398
8	Developmental and tissue-specific expression of the Q5k gene. <i>Immunogenetics</i> , <b>1991</b> , 34, 28-38	3.2	14
7	The physiology of the NF- <b>B</b> transcription factor. <i>Molecular Aspects of Cellular Regulation</i> , <b>1991</b> , 6, 423-446		55
6	The NF-kappa B transcription factor induces DNA bending which is modulated by its 65-kD subunit. <i>Nucleic Acids Research</i> , <b>1990</b> , 18, 6497-502	20.1	112
5	The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. <i>Cell</i> , <b>1990</b> , 62, 1007-18	56.2	902
4	Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA. <i>Cell</i> , <b>1990</b> , 61, 255-65	56.2	412
3	Tumor necrosis factor beta (TNF-beta) induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in the TNF-beta promoter. <i>Cytokine</i> , <b>1990</b> , 2, 389-97	4	54
2	Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. <i>Cell</i> , <b>1988</b> , 53, 211-7	56.2	1152
1	Rationale for Treatment of Colorectal Cancer with EpCAM Targeting Therapeutics179-200		